The investment, which values Juvenescence at $400 million, tees the anti-aging startup to advance its multiasset pipeline.

Brainsway, developer of transcranial magnetic device treatments for depression and OCD, plans to raise $30 million through a Nasdaq IPO.

While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there are becoming untenable for some.

Seres Therapeutics is promoting its chief operating and financial officer, Eric Shaff, to succeed Roger Pomerantz as its new president and CEO.

Aimmune has confirmed that the government shutdown will delay the FDA’s review of AR101, its oral immunotherapy for peanut allergy.

Roche's Omar Khwaja, M.D., Ph.D., will become chief medical officer at gene therapy specialist Voyager Therapeutics.

Paul Streck, M.D., will this week exit his role as chief medical officer of Insmed to “pursue an employment opportunity on the West Coast.”

Berman spent the past decade overseeing the rise of immuno-oncology drugs at AstraZeneca and Bristol-Myers Squibb.